Precision Medicine in Myeloma

Challenges in Defining an Actionable Approach

Verónica González-Calle, Niamh Keane, Esteban D Braggio, Rafael Fonseca

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recently, large sequencing studies have provided insights into the mutational landscape of multiple myeloma (MM), identifying actionable mutations and giving a precious opportunity for exploring new targeted therapies. The main goal of precision medicine, matching patients with the right drug, seems to be closer than ever. However, no targeted therapies in MM are approved yet. Several clinical trials testing targeted drugs and enrolling patients with MM are currently ongoing and will provide predictive biomarkers that might support clinical decision making. In this review, we evaluate the evidence supporting the implementation of precision medicine in MM and we discuss the challenges that should be dealt with in this imminent and promising new era.

Original languageEnglish (US)
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
StateAccepted/In press - 2017

Fingerprint

Precision Medicine
Multiple Myeloma
Patient Rights
Pharmaceutical Preparations
Biomarkers
Clinical Trials
Mutation
Therapeutics

Keywords

  • Actionable mutation
  • Driver
  • Immunotherapy
  • Multiple myeloma
  • Target therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Precision Medicine in Myeloma : Challenges in Defining an Actionable Approach. / González-Calle, Verónica; Keane, Niamh; Braggio, Esteban D; Fonseca, Rafael.

In: Clinical Lymphoma, Myeloma and Leukemia, 2017.

Research output: Contribution to journalArticle

@article{e8468d1c062c4efd8f76d91c0aaa943f,
title = "Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach",
abstract = "Recently, large sequencing studies have provided insights into the mutational landscape of multiple myeloma (MM), identifying actionable mutations and giving a precious opportunity for exploring new targeted therapies. The main goal of precision medicine, matching patients with the right drug, seems to be closer than ever. However, no targeted therapies in MM are approved yet. Several clinical trials testing targeted drugs and enrolling patients with MM are currently ongoing and will provide predictive biomarkers that might support clinical decision making. In this review, we evaluate the evidence supporting the implementation of precision medicine in MM and we discuss the challenges that should be dealt with in this imminent and promising new era.",
keywords = "Actionable mutation, Driver, Immunotherapy, Multiple myeloma, Target therapy",
author = "Ver{\'o}nica Gonz{\'a}lez-Calle and Niamh Keane and Braggio, {Esteban D} and Rafael Fonseca",
year = "2017",
doi = "10.1016/j.clml.2017.06.021",
language = "English (US)",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",

}

TY - JOUR

T1 - Precision Medicine in Myeloma

T2 - Challenges in Defining an Actionable Approach

AU - González-Calle, Verónica

AU - Keane, Niamh

AU - Braggio, Esteban D

AU - Fonseca, Rafael

PY - 2017

Y1 - 2017

N2 - Recently, large sequencing studies have provided insights into the mutational landscape of multiple myeloma (MM), identifying actionable mutations and giving a precious opportunity for exploring new targeted therapies. The main goal of precision medicine, matching patients with the right drug, seems to be closer than ever. However, no targeted therapies in MM are approved yet. Several clinical trials testing targeted drugs and enrolling patients with MM are currently ongoing and will provide predictive biomarkers that might support clinical decision making. In this review, we evaluate the evidence supporting the implementation of precision medicine in MM and we discuss the challenges that should be dealt with in this imminent and promising new era.

AB - Recently, large sequencing studies have provided insights into the mutational landscape of multiple myeloma (MM), identifying actionable mutations and giving a precious opportunity for exploring new targeted therapies. The main goal of precision medicine, matching patients with the right drug, seems to be closer than ever. However, no targeted therapies in MM are approved yet. Several clinical trials testing targeted drugs and enrolling patients with MM are currently ongoing and will provide predictive biomarkers that might support clinical decision making. In this review, we evaluate the evidence supporting the implementation of precision medicine in MM and we discuss the challenges that should be dealt with in this imminent and promising new era.

KW - Actionable mutation

KW - Driver

KW - Immunotherapy

KW - Multiple myeloma

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=85025107555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025107555&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2017.06.021

DO - 10.1016/j.clml.2017.06.021

M3 - Article

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

ER -